WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) received the 2026 Healthcare & Life Sciences Company of the Year award from the Philadelphia Alliance for Capital and Technologies as the clinical-stage biotechnology company advances late-stage therapies targeting rare vascular and skin disorders with no approved FDA treatments.
The recognition comes as Palvella moves toward potential regulatory filings for QTORIN rapamycin, its lead therapy candidate for microcystic lymphatic malformations and cutaneous venous malformations.
PACT stated the award recognizes companies demonstrating clinical advancement, product development, capital formation, and broader impact within the Greater Philadelphia life sciences sector.
The Philadelphia region has continued attracting investment and expansion across biotechnology and specialty therapeutics, with emerging companies increasingly competing for funding and regulatory milestones in rare disease markets.
Palvella has focused its development efforts on therapies targeting vascular malformations and rare dermatologic disorders, areas with limited approved treatment options and relatively small patient populations that can qualify for expedited FDA regulatory pathways.
Chief Executive Officer Wes Kaupinen stated the recognition reflects the company’s clinical and operational progress within the regional biotechnology industry.
“We are proud to be building Palvella in Greater Philadelphia alongside one of the country’s most dynamic and growing innovative life sciences communities,” Kaupinen stated.
PACT evaluates award candidates based on product innovation, clinical and commercial advancement, fundraising activity, and contribution to the regional healthcare and technology ecosystem.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.